4th Quarter - Report

THE UNITED STATES PHARMACOPEIAL CONVENTION for THE UNITED STATES PHARMACOPEIAL CONVENTION

Firm
Client
Income
—
Expenses
$50,000
Expense method
B: tax-exempt organisations, Internal Revenue Code section 6033(b)(8)

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

H.R. 2617: The Consolidated Appropriations Act of 2023 - Provisions related to pharmaceutical supply chain resiliency and national centers of excellence in advanced pharmaceutical manufacturing.

LobbyistCovered position, as disclosed
JOSEPH M. HILL —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 2617 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.